Analyst Price Targets — TGTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 22, 2026 7:56 pm | — | Jefferies | $83.00 | $54.40 | TheFly | TG Therapeutics price target raised to $83 from $57 at Jefferies |
| May 6, 2026 3:54 pm | — | H.C. Wainwright | $70.00 | $39.75 | TheFly | TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright |
| January 15, 2026 12:51 am | — | Goldman Sachs | $39.00 | $29.54 | TheFly | TG Therapeutics price target raised to $39 from $37 at Goldman Sachs |
| October 6, 2025 10:11 am | Emily Bodnar | H.C. Wainwright | $60.00 | $36.71 | TheFly | TG Therapeutics assumed with a Buy at H.C. Wainwright |
| November 5, 2024 11:41 am | Edward White | H.C. Wainwright | $27.50 | $12.93 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright |
| August 6, 2024 6:02 pm | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | TheFly | TG Therapeutics price target raised to $20 from $18 at Goldman Sachs |
| May 3, 2024 6:46 am | Edward White | H.C. Wainwright | $24.50 | $8.21 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright |
| February 7, 2023 7:34 am | — | Cantor Fitzgerald | $24.00 | $18.48 | Benzinga | Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24 |
| December 30, 2022 9:21 am | — | Evercore ISI | $16.00 | $11.83 | Benzinga | Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16 |
| December 29, 2022 6:10 am | Edward White | H.C. Wainwright | $12.00 | $4.23 | TheFly | TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright |
Latest News for TGTX
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TGTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.